Rani Therapeutics Holdings (RANI) Operating Leases (2022 - 2026)

Rani Therapeutics Holdings has reported Operating Leases for 5 years, with the latest figure at $2.2 million in Q2 2026.

• On a quarterly basis, Operating Leases fell 30.6% year-over-year to $2.2 million in Q2 2026; TTM through Jun 2026 was $2.2 million, a 30.6% decrease from a year earlier, with the FY2025 full-year figure at $2.7 million, down 24.88% from the prior year.
• Operating Leases was $2.2 million for Q2 2026 at Rani Therapeutics Holdings, down from $2.5 million in the prior quarter.
• The five-year high for Operating Leases was $4.7 million in Q1 2024, with the low at $59000.0 in Q4 2022.
• Average Operating Leases over 5 years is $2.1 million, with a median of $2.5 million recorded in 2026.
• The sharpest annual moves came in 2023 and 2024: Operating Leases slumped 46.23% in 2023, then jumped 2249.12% in 2024.
• Over 5 years, Operating Leases stood at $59000.0 in 2022, then jumped by 189.83% to $171000.0 in 2023, then surged by 2026.9% to $3.6 million in 2024, then dropped by 24.88% to $2.7 million in 2025, then slipped by 18.74% to $2.2 million in 2026.
• The last three Operating Leases figures came in at $2.2 million (Q2 2026), $2.5 million (Q1 2026), and $2.7 million (Q4 2025), per Business Quant data.